Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML. (2020)
Attributed to:
Epigenomic Mechanisms of Action of Novel Mutant Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukaemia
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/bloodadvances.2020001503
PubMed Identifier: 32380538
Publication URI: http://europepmc.org/abstract/MED/32380538
Type: Journal Article/Review
Volume: 4
Parent Publication: Blood advances
Issue: 9
ISSN: 2473-9529